+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Nav1.7 Blockers -Pipeline Insights, 2016

  • ID: 3534476
  • Drug Pipelines
  • 60 pages
  • DelveInsight
1 of 3
“Nav1.7 Blockers-Pipeline Insights, 2016” report provides in depth insights on the pipeline drugs and their development activities around the Nav1.7 Blockers. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Nav1.7 Blockers. The Report also assesses the Nav1.7 Blockers therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.
Note: Product cover images may vary from those shown
2 of 3
Table of Contents
- Nav1.7 Blockers Overview
- Nav1.7 Blockers Disease Associated
- Nav1.7 Blockers Pipeline Therapeutics
- Nav1.7 Blockers Therapeutics under Development by Companies
- Nav1.7 Blockers Filed and Phase III Products
- Comparative Analysis
- Nav1.7 Blockers Phase II Products
- Comparative Analysis
- Nav1.7 Blockers Phase I and IND Filed Products
- Comparative Analysis
- Nav1.7 Blockers Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Nav1.7 Blockers – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nav1.7 Blockers – Discontinued Products
- Nav1.7 Blockers – Dormant Products
- Companies Involved in Therapeutics Development for Nav1.7 Blockers
- Appendix
- Methodology
- Contact Us
- Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
- The report provides competitive pipeline landscape of Nav1.7 Blockers
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Nav1.7 Blockers pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Nav1.7 Blockers and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Note: Product cover images may vary from those shown